CliffBio
biologic

Poteligeo

mogamulizumab-kpkc

Loss of exclusivityAugust 2030projected — 12-year biologic exclusivity estimate
CompanyKyowa Kirin Co. →See this company's full patent-cliff portfolio

Drug detail

Brand namePoteligeo
Active ingredientmogamulizumab-kpkc
Strength20MG/5ML (4MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2018
Marketing statusRx

More from Kyowa Kirin Co.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.